JP2024539193A5 - - Google Patents
Info
- Publication number
- JP2024539193A5 JP2024539193A5 JP2024523783A JP2024523783A JP2024539193A5 JP 2024539193 A5 JP2024539193 A5 JP 2024539193A5 JP 2024523783 A JP2024523783 A JP 2024523783A JP 2024523783 A JP2024523783 A JP 2024523783A JP 2024539193 A5 JP2024539193 A5 JP 2024539193A5
- Authority
- JP
- Japan
- Prior art keywords
- rnai agent
- nucleotide
- agent according
- modified
- nucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163270849P | 2021-10-22 | 2021-10-22 | |
| US63/270,849 | 2021-10-22 | ||
| US202263308289P | 2022-02-09 | 2022-02-09 | |
| US63/308,289 | 2022-02-09 | ||
| US202263345654P | 2022-05-25 | 2022-05-25 | |
| US63/345,654 | 2022-05-25 | ||
| PCT/US2022/078498 WO2023070082A2 (en) | 2021-10-22 | 2022-10-21 | Rnai agents for inhibiting expression of matrix metalloproteinase 7(mmp7), compositions thereof, and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024539193A JP2024539193A (ja) | 2024-10-28 |
| JP2024539193A5 true JP2024539193A5 (cg-RX-API-DMAC7.html) | 2025-10-28 |
Family
ID=86059695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024523783A Pending JP2024539193A (ja) | 2021-10-22 | 2022-10-21 | マトリックスメタロプロテイナーゼ7(MMP7)の発現を抑制するためのRNAi剤、その組成物、及び使用の方法 |
Country Status (13)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2025014897A (es) * | 2023-06-13 | 2026-02-03 | Tuojie Biotech Shanghai Co Ltd | Arnip dirigido a mmp7, conjugado de arnip y su uso medico |
| CN121693569A (zh) | 2023-07-28 | 2026-03-17 | 长春金赛药业有限责任公司 | siRNA及其组合物 |
| WO2025152967A1 (zh) * | 2024-01-15 | 2025-07-24 | 武汉人福创新药物研发中心有限公司 | 靶向αvβ6的化合物及其用途 |
| WO2025228156A1 (zh) * | 2024-04-30 | 2025-11-06 | 北京炫景瑞医药科技有限公司 | 肾靶向的双链寡核苷酸缀合物及其用途 |
| WO2026130467A1 (zh) * | 2024-12-18 | 2026-06-25 | 上海拓界生物医药科技有限公司 | 一种RNAi剂及其医药用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030194704A1 (en) * | 2002-04-03 | 2003-10-16 | Penn Sharron Gaynor | Human genome-derived single exon nucleic acid probes useful for gene expression analysis two |
| US20050118625A1 (en) * | 2003-10-02 | 2005-06-02 | Mounts William M. | Nucleic acid arrays for detecting gene expression associated with human osteoarthritis and human proteases |
| WO2006092795A2 (en) * | 2005-03-01 | 2006-09-08 | Qbi Enterprises Ltd. | Oligoribonucleotides and methods of use thereof for treatment of ocular scarring and other fibrotic conditions |
| SG11202002967SA (en) * | 2017-11-01 | 2020-05-28 | Arrowhead Pharmaceuticals Inc | Integrin ligands and uses thereof |
| CA3082591A1 (en) * | 2017-11-15 | 2019-05-23 | Beth Israel Deaconess Medical Center, Inc. | Markers for the diagnosis and treatment of non-alcoholic steatohepatitis (nash) and advanced liver fibrosis |
| TW202130809A (zh) * | 2019-10-29 | 2021-08-16 | 美商愛羅海德製藥公司 | 用於抑制β-ENaC表現之RNAi藥劑、其組合物及使用方法 |
| WO2022056286A1 (en) * | 2020-09-11 | 2022-03-17 | Arrowhead Pharmaceuticals, Inc. | Integrin targeting ligands and uses thereof |
-
2022
- 2022-10-21 MX MX2024004912A patent/MX2024004912A/es unknown
- 2022-10-21 CA CA3235224A patent/CA3235224A1/en active Pending
- 2022-10-21 PE PE2024000898A patent/PE20241185A1/es unknown
- 2022-10-21 US US18/048,577 patent/US20230265437A1/en active Pending
- 2022-10-21 WO PCT/US2022/078498 patent/WO2023070082A2/en not_active Ceased
- 2022-10-21 JP JP2024523783A patent/JP2024539193A/ja active Pending
- 2022-10-21 AU AU2022368927A patent/AU2022368927A1/en active Pending
- 2022-10-21 EP EP22884722.4A patent/EP4419689A4/en active Pending
- 2022-10-21 IL IL312239A patent/IL312239A/en unknown
- 2022-10-21 TW TW111140110A patent/TW202334416A/zh unknown
- 2022-10-21 KR KR1020247016352A patent/KR20240099296A/ko active Pending
-
2024
- 2024-04-15 CL CL2024001175A patent/CL2024001175A1/es unknown
- 2024-04-23 CO CONC2024/0005110A patent/CO2024005110A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025185070A5 (cg-RX-API-DMAC7.html) | ||
| JP2024516096A5 (cg-RX-API-DMAC7.html) | ||
| JP2020526192A5 (cg-RX-API-DMAC7.html) | ||
| JP2025128190A5 (cg-RX-API-DMAC7.html) | ||
| JP2023519246A5 (cg-RX-API-DMAC7.html) | ||
| JP7697889B2 (ja) | アルファ-1アンチトリプシン欠乏症(aatd)の治療法 | |
| TW201803989A (zh) | 拮抗b型肝炎病毒之組成物和藥劑及彼等之用途 | |
| JP2016523863A5 (cg-RX-API-DMAC7.html) | ||
| CN1247473A (zh) | 治疗与呼吸失调和肺部炎症相关的疾病和症状的药剂和方法 | |
| JP2023536999A (ja) | B型肝炎患者のオリゴヌクレオチド処置 | |
| CN107073114A (zh) | 使用瑞利珠单抗治疗中度到重度嗜酸细胞性哮喘 | |
| ES2301659T3 (es) | Metodos para aumentar la eficacia in vivo de oligonucleotidos e inhibir la inflamacion en mamiferos. | |
| JP2024515880A5 (cg-RX-API-DMAC7.html) | ||
| JP2024520522A5 (cg-RX-API-DMAC7.html) | ||
| JP2015532100A (ja) | アンフィレギュリンに特異的な二重鎖オリゴrna、そのような二重鎖オリゴrnaを含む二重鎖オリゴrnaの構造体及びこれを含む呼吸器疾患の予防または治療用の組成物 | |
| JP2023547274A (ja) | マイクロrna-29の化合物、組成物、および治療法における使用 | |
| JP2023541170A (ja) | Z-aatタンパク質のレベルを低下させる方法 | |
| CN105126112A (zh) | 卵磷脂化超氧化物歧化酶作为有效成分在制备慢性阻塞性肺疾病改善剂中的应用 | |
| US20240309383A1 (en) | Small interfering rna targeting hbv and uses thereof | |
| Wang et al. | Mucosal and transdermal delivery strategies for mRNA: Transforming the clinical applications | |
| JP7514563B2 (ja) | オルガノイドおよび抗炎症剤を含む炎症性腸疾患の予防または治療用薬学組成物 | |
| CN118019545A (zh) | 缓解或治疗纤维化性疾病的药物组合物或药盒及其应用 | |
| JP2024026903A (ja) | siRNA及び医薬組成物並びに予防及び/又は治療剤 | |
| AU2013226216B2 (en) | Method of treating chronic obstructive pulmonary disease | |
| US20260103712A1 (en) | Anti-fibrotic microrna composition |